Over the last 7 days, the United States market has risen by 2.4%, contributing to a remarkable 25% climb over the past year, with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying small-cap stocks that are currently undervalued and exhibit insider activity can present intriguing opportunities for investors seeking potential growth.
Name | PE | PS | Discount to Fair Value | Value Rating |
---|---|---|---|---|
OptimizeRx | NA | 1.1x | 44.15% | ★★★★★☆ |
Quanex Building Products | 33.3x | 0.9x | 38.67% | ★★★★☆☆ |
First United | 13.0x | 3.0x | 47.13% | ★★★★☆☆ |
Franklin Financial Services | 10.4x | 2.0x | 33.90% | ★★★★☆☆ |
McEwen Mining | 4.3x | 2.2x | 44.35% | ★★★★☆☆ |
Innovex International | 9.2x | 2.1x | 47.28% | ★★★★☆☆ |
ChromaDex | 305.2x | 4.9x | 29.74% | ★★★☆☆☆ |
ProPetro Holding | NA | 0.8x | 11.49% | ★★★☆☆☆ |
Delek US Holdings | NA | 0.1x | -75.07% | ★★★☆☆☆ |
Sabre | NA | 0.4x | -64.39% | ★★★☆☆☆ |
Click here to see the full list of 45 stocks from our Undervalued US Small Caps With Insider Buying screener.
Let's explore several standout options from the results in the screener.
Simply Wall St Value Rating: ★★★☆☆☆
Overview: ChromaDex is a bioscience company focused on developing and commercializing dietary supplements and ingredients, with a market cap of $0.19 billion.
Operations: ChromaDex's revenue is primarily derived from consumer products, followed by ingredients and analytical reference standards and services. The company's gross profit margin has shown an upward trend, reaching 61.45% in the latest period. Operating expenses are a significant cost component, with general and administrative expenses being the largest contributor.
PE: 305.2x
ChromaDex, a smaller player in the U.S. market, is gaining attention for its innovative health products like Niagen IV, now available nationwide. Despite a volatile share price recently, their financials show promise with Q3 2024 sales hitting US$25.58 million, up from US$19.5 million the previous year. Insider confidence is evident as individuals within the company have been purchasing shares over recent months, signaling potential growth optimism amidst projected revenue increases and expanding product lines.
Gain insights into ChromaDex's historical performance by reviewing our past performance report.
Simply Wall St Value Rating: ★★★☆☆☆
Overview: SNDL is a company engaged in liquor retail, cannabis retail, and cannabis operations with a market capitalization of CA$1.09 billion.
Operations: The company generates revenue primarily through liquor retail, cannabis retail, and cannabis operations. The gross profit margin has shown an upward trend, reaching 25.12% as of the latest reporting period.
PE: -6.0x
SNDL, a small company in the cannabis industry, is navigating its financial challenges with strategic initiatives. Despite being unprofitable and reliant on external funding, they are actively pursuing growth through collaborations like their recent agreement with HYTN Innovations to develop GMP-compliant vape cartridges. Insider confidence is evident as leadership changes bring experienced individuals onboard, enhancing digital transformation and operational efficiency. A share repurchase program aims to return value to shareholders while exploring acquisitions signals potential for future expansion.
Examine SNDL's past performance report to understand how it has performed in the past.
Simply Wall St Value Rating: ★★★★☆☆
Overview: Potbelly operates a chain of sandwich shops and has a market capitalization of $0.1 billion.
Operations: The company generates revenue primarily through its sandwich shops, with a recent gross profit margin of 35.50%. Cost of goods sold (COGS) and operating expenses are significant components of its cost structure, impacting net income.
PE: 8.5x
Potbelly, a smaller company in the U.S., is navigating its growth path with strategic franchise expansions and insider confidence reflected in recent share purchases. The company reported a rise in net income to US$3.74 million for Q3 2024, despite a drop in revenue to US$115.12 million compared to the previous year. However, future earnings are projected to decline significantly over the next three years. Recent auditor changes and modest share repurchases indicate an ongoing restructuring effort aimed at long-term stability and growth potential through its Franchise Growth Acceleration Initiative, targeting 2,000 shops nationwide.
Explore historical data to track Potbelly's performance over time in our Past section.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NasdaqCM:CDXC NasdaqCM:SNDL and NasdaqGS:PBPB.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.